A Phase 3b, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination in Treatment-Naive and Treatment-Experienced Korean and Taiwanese Subjects With Chronic Genotype 1 HCV Infection
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 20 Jul 2017
At a glance
- Drugs Ledipasvir/sofosbuvir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Gilead Sciences
- 06 Feb 2017 Status changed from recruiting to active, no longer recruiting.
- 07 Jul 2016 Status changed from active, no longer recruiting to recruiting.
- 31 Mar 2016 Planned End Date changed from 1 Apr 2017 to 1 Oct 2017 as reported by ClinicalTrials.gov.